Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00464269
First received: April 19, 2007
Last updated: August 26, 2014
Last verified: September 2013
  Purpose

This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Condition Intervention Phase
Epilepsy
Other: Placebo
Drug: Brivaracetam
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study; Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures

Resource links provided by NLM:


Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Partial onset seizure (Type I) frequency per week over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Partial onset seizure (Type I) frequency per week over the 12-week Treatment Period


Secondary Outcome Measures:
  • Responder rate for partial onset seizures (Type I) frequency per week over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Responder rate for partial onset seizures (Type I) frequency per week over the 12-week Treatment Period

  • All seizure frequency (Type I+II+III) per week over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    All seizure frequency (Type I+II+III) per week over the 12-week Treatment Period

  • Percent change from Baseline to the 12-week Treatment Period in partial onset seizure (Type I) frequency per week [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Percent change from Baseline to the 12-week Treatment Period in partial onset seizure (Type I) frequency per week

  • Categorized percentage change from Baseline in seizure frequency for partial onset seizure (Type I) over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Categorized percentage change from Baseline in seizure frequency for partial onset seizure (Type I) over the 12-week Treatment Period

  • Seizure freedom rate (all seizure types) over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Seizure freedom rate (all seizure types) over the 12-week Treatment Period

  • Time to first Type I seizure during the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Time to first Type I seizure during the 12-week Treatment Period

  • Time to fifth Type I seizure during the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Time to fifth Type I seizure during the 12-week Treatment Period

  • Time to tenth Type I seizure during the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Time to tenth Type I seizure during the 12-week Treatment Period

  • Reduction of Type IC/Type I seizure frequency ratio from Baseline to the 12- week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Reduction of Type IC/Type I seizure frequency ratio from Baseline to the 12- week Treatment Period

  • Change from Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score

  • Change from Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score

  • Change from Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score [ Time Frame: Basline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score

  • Change from Baseline to the 12-week Treatment Period in Hospital Anxiety score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Hospital Anxiety score

  • Change from Baseline to the 12-week Treatment Period in Hospital Depression score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Hospital Depression score

  • Patient's Global Evaluation Scale (P-GES) evaluated at Last Visit or Early Discontinuation Visit [ Time Frame: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period ] [ Designated as safety issue: No ]
    Patient's Global Evaluation Scale (P-GES) evaluated at Last Visit or Early Discontinuation Visit

  • Investigator's Global Evaluation Scale (I-GES) evaluated at Last Visit or Early Discontinuation Visit [ Time Frame: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period ] [ Designated as safety issue: No ]
    Investigator's Global Evaluation Scale (I-GES) evaluated at Last Visit or Early Discontinuation Visit


Enrollment: 400
Study Start Date: September 2007
Study Completion Date: January 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Matching Placebo tablets administered twice a day
Other: Placebo
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week treatment period
Experimental: Brivaracetam 5 mg/day
Brivaracetam 5 mg/day, 2.5 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment period
Experimental: BRV 20mg/day
Brivaracetam 20 mg/day, 10 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment period
Experimental: BRV 50mg/day
Brivaracetam 50 mg/day, 25 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening,of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment period

  Eligibility

Ages Eligible for Study:   16 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects were 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
  • Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
  • Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
  • Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1 (V1)
  • Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
  • Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drug(s) (AEDs). Vagal nerve stimulation (VNS) was allowed and was not counted as a concomitant AED

Exclusion Criteria:

  • History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
  • History or presence of status epilepticus during the year preceding Visit 1 or during Baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00464269

  Show 70 Study Locations
Sponsors and Collaborators
UCB Pharma
Investigators
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

No publications provided by UCB Pharma

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: UCB Pharma
ClinicalTrials.gov Identifier: NCT00464269     History of Changes
Other Study ID Numbers: N01253, 2006-006345-14
Study First Received: April 19, 2007
Last Updated: August 26, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Brazil: National Health Surveillance Agency
Mexico: Federal Commission for Protection Against Health Risks
Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by UCB Pharma:
Epilepsy
Brivaracetam
Partial Onset Seizures, Adolescents & Adults

Additional relevant MeSH terms:
Epilepsy
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on November 25, 2014